Pfizer is buying the company Global Blood Therapeutics for $5.4 billion dollars. Global Blood is a blood disorder drugmaker. Pfizer is paying $68.50 per share, which is 7.3% more than the share price at the time of Friday’s closing. Pfizer has had a huge boom in sales ever since they made their Covid-19 vaccine. The sales have started to slow down however, so the company is looking to buy different companies that could help them make a lot of money. Pfizer has already bought Biohaven Pharmaceutical Holding for $11.6 billion and Arena Pharmaceuticals for $6.7 billion.
Source: https://www.cnbc.com/2022/08/08/pfizer-to-buy-global-blood-therapeutics-in-5point4-billion-deal.html
